Effects of substance P and Sar-Met-SP, a NK1 agonist, in distinct amygdaloid nuclei on anxiety-like behavior in rats.
The amygdala, together with the dorsal periaqueductal gray (dPAG), medial hypothalamus, and deep layers of the superior and inferior colliculi, constitutes the encephalic aversion system, which has been considered the main neural substrate for the organization of fear and anxiety. The basolateral nucleus of the amygdala (BLA) acts as a filter for aversive stimuli to higher structures while the central (CeA) and the medial (MeA) nuclei constitute the output for the autonomic and somatic components of the emotional reaction through major projections to the limbic and brainstem regions. Although some findings point to the distinct participation of the substance P (SP) and the NK1 receptors system in the different nuclei of the amygdala on the expression of emotional behaviors, it is not clear if this system modulates anxiety-like responses in the distinct nuclei of the amygdala as well as the dPAG. Thus, it was investigated if the injection of SP into the BLA, CeA, or MeA affects the expression of anxiety-like responses of rats submitted to the elevated plus-maze (EPM) test and, if the effects are mediated by NK1 receptors. The results showed that SP and Sar-Met-SP (NK1 receptor selective agonist) injected into the CeA and MeA, but not into the BLA, caused anxiogenic-like effects in the EPM. Altogether, the data indicates that the SP may mimic the effects of anxiogenic stimuli via NK1 receptor activation only in the CeA and MeA (amygdala's nuclei output) and may activate the neural mechanisms involved in the defensive reaction genesis. The SP/NK1 receptors system activation may be phasically involved in very specific aspects of anxiety behaviors.
Instituto de Neurociências e Comportamento, Av. do Café, 2.450, 14050-220 Ribeirão Preto, SP, Brazil; Laboratório de Neuropsicofarmacologia, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto (FFCLRP), Universidade de São Paulo (USP), Av. dos Bandeirantes, 3900, 14040-901 Ribeirão Preto, SP, Brazil.
Gabriel Shimizu
GS
Bassi
Instituto de Neurociências e Comportamento, Av. do Café, 2.450, 14050-220 Ribeirão Preto, SP, Brazil; Laboratório de Neuropsicofarmacologia, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto (FFCLRP), Universidade de São Paulo (USP), Av. dos Bandeirantes, 3900, 14040-901 Ribeirão Preto, SP, Brazil. Electronic address: mccarva@usp.br.
Milene Cristina
MC
de Carvalho
Instituto de Neurociências e Comportamento, Av. do Café, 2.450, 14050-220 Ribeirão Preto, SP, Brazil; Laboratório de Neuropsicofarmacologia, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto (FFCLRP), Universidade de São Paulo (USP), Av. dos Bandeirantes, 3900, 14040-901 Ribeirão Preto, SP, Brazil.
Marcus Lira
ML
Brandão
D000818:Animals; D001007:Anxiety / Q000523:psychology*; D066274:Central Amygdaloid Nucleus / Q000187:drug effects*; D066276:Corticomedial Nuclear Complex / Q000187:drug effects*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008845:Microinjections; D017208:Rats, Wistar; D018040:Receptors, Neurokinin-1 / Q000819:agonists*; D013373:Substance P / Q000031:analogs & derivatives* / Q000494:pharmacology*
D018040:Receptors, Neurokinin-1; C062618:substance P, Sar(9)-Met(O2)(11)-; D013373:Substance P
Amygdala; Anxiety; Elevated plus maze; NK-1 receptors; Substance P